Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease insights from getting to an improved understanding of low-density lipoprotein cholesterol and dyslipidemia management (GOULD)

Circulation

Volumn 140, Issue 7, 2019, Pages 618-620

  Arnold, Suzanne V ^a   De Lemos, James A ^b   Rosenson, Robert S ^c   Ballantyne, Christie M ^d   Liu, Yuyin ^e   Mues, Katherine E ^f   Alam, Shushama ^f   Elliott Davey, Mary ^f   Bhatt, Deepak L ^g   Cannon, Christopher P ^e,g   Kosiborod, Mikhail ^h  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^f AMGEN INC   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

Author keywords

Coronary artery disease; Diabetes mellitus; Quality of care

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EZETIMIBE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PROPROTEIN CONVERTASE 9; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL OUTCOME; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; LETTER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK REDUCTION;

EID: 85071353088     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.119.041730     Document Type: Letter

References (5)

1. Bittner V, Bertolet M, Barraza Felix R, Farkouh ME, Goldberg S, Ramanathan KB, Redmon JB, Sperling L, Rutter MK; BARI 2D Study Group. Comprehensive cardiovascular risk factor control improves survival: the BARI 2D Trial. J Am Coll Cardiol. 2015;66:765-773. doi: 10.1016/j.jacc.2015.06.019
2. Chen SJ, Liu W, Huang BT, Tsauo JY, Pu XB, Peng Y, Chen M, Huang DJ. The impact of optimal medical therapy at discharge on mortality in patients with coronary artery disease. J Geriatr Cardiol. 2017;14:100-107. doi: 10.11909/j.issn.1671-5411.2017.02.004
3. American Diabetes A. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S103-S123.
4. Arnold SV, Inzucchi SE, Tang F, McGuire DK, Mehta SN, Maddox TM, Goyal A, Sperling LS, Einhorn D, Wong ND, et al. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR® Research to Practice project. Eur J Prev Cardiol. 2017;24:1637-1645. doi: 10.1177/2047487317729252
5. Giugliano R P, Cannon C P, Blazing MA, Nicolau JC, Corbalán R, Špinar J, Park JG, White JA, Bohula EA, Braunwald E; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Effcacy International Trial) Investigators. Beneft of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Effcacy International Trial). Circulation. 2018;137:1571-1582. doi: 10.1161/CIRCULATIONAHA.117.030950